

---

STATUTORY INSTRUMENTS

---

**2019 No. 775**

**The Human Medicines (Amendment  
etc.) (EU Exit) Regulations 2019**

**PART 5**

Amendment of Part 5 (marketing authorisations)

**[<sup>F1</sup>Amendment of regulation 79 (failure to provide information on marketing authorisations to EMA)**

- 88.** In regulation 79 (failure to provide information on marketing authorisations to EMA)—
- (a) in paragraph (1), for the first reference to “a marketing authorisation” substitute “a UKMA(NI) or UKMA(UK)”;
  - (b) in paragraph (2), for the first reference to “a marketing authorisation” substitute “UKMA(NI) or UKMA(UK)”.]

**Textual Amendments**

- F1** Reg. 88 substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, [Sch. 2 para. 65](#)

**Commencement Information**

- I1** Reg. 88 in force at 31.12.2020 on IP completion day (in accordance with [2020 c. 1](#), [Sch. 5 para. 1\(1\)](#)), see [reg. 1](#)

**Changes to legislation:**

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 88.